{"schema_version":"secwatch.filing_event.v1","accession":"0001802768-25-000113","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.508182+00:00","generated_at":"2026-05-17T00:22:28.968868+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Royalty Pharma Q3 Portfolio Receipts +11% to $814M; raises FY guidance to $3,200-$3,250M","bullets":["Portfolio Receipts $814M (+11% YoY); Royalty Receipts $811M (+11%). Net cash ops $703M.","Raised FY 2025 guidance: Portfolio Receipts now $3,200-$3,250M (14-16% growth, previously $3,050-$3,150M).","Adjusted EBITDA $779M, Portfolio Cash Flow $657M. Capital Deployment $1.0B in Q3 (Imdelltra, obexelimab, Amvuttra).","Repurchased 4M shares for $152M in Q3; $1.2B YTD share repurchases.","Issued $2B senior notes at 5.16% in Sep; repaid $1B notes in Aug; total debt $9.2B at 3.75% avg cost."],"urls":{"canonical":"https://secwatch.observer/filing/0001802768-25-000113","json":"https://secwatch.observer/filing/0001802768-25-000113.json","markdown":"https://secwatch.observer/filing/0001802768-25-000113.md","text":"https://secwatch.observer/filing/0001802768-25-000113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000113/0001802768-25-000113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000113/rprx-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:22:28.968868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}